Atomoxetine in the treatment of attention deficit hyperactivity disorder

Christopher J Kratochvil, Brigette S. Vaughan, Joan M. Daughton, Michelle L. Mayfield-Jorgensen, William J. Burke

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Atomoxetine (Strattera™ Eli Lilly & Co.) is a highly selective noradrenaline reuptake inhibitor and the first nonstimulant medication to be approved for the treatment of attention deficit hyperactivity disorder. Currently, nine published clinical trials have documented the safety and efficacy of atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder and data presented throughout the past year at national scientific meetings has further addressed its utility. This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use.

Original languageEnglish (US)
Pages (from-to)601-611
Number of pages11
JournalExpert Review of Neurotherapeutics
Volume4
Issue number4
DOIs
StatePublished - Jul 1 2004

Fingerprint

Attention Deficit Disorder with Hyperactivity
Therapeutics
Norepinephrine
Clinical Trials
Safety
Atomoxetine Hydrochloride

Keywords

  • Atomoxetine
  • Attention deficit hyperactivity disorder
  • Norepinephrine
  • Psychopharmacology

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Atomoxetine in the treatment of attention deficit hyperactivity disorder. / Kratochvil, Christopher J; Vaughan, Brigette S.; Daughton, Joan M.; Mayfield-Jorgensen, Michelle L.; Burke, William J.

In: Expert Review of Neurotherapeutics, Vol. 4, No. 4, 01.07.2004, p. 601-611.

Research output: Contribution to journalReview article

Kratochvil, Christopher J ; Vaughan, Brigette S. ; Daughton, Joan M. ; Mayfield-Jorgensen, Michelle L. ; Burke, William J. / Atomoxetine in the treatment of attention deficit hyperactivity disorder. In: Expert Review of Neurotherapeutics. 2004 ; Vol. 4, No. 4. pp. 601-611.
@article{42da388d58fd421397ea31a6fb90f4d4,
title = "Atomoxetine in the treatment of attention deficit hyperactivity disorder",
abstract = "Atomoxetine (Strattera™ Eli Lilly & Co.) is a highly selective noradrenaline reuptake inhibitor and the first nonstimulant medication to be approved for the treatment of attention deficit hyperactivity disorder. Currently, nine published clinical trials have documented the safety and efficacy of atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder and data presented throughout the past year at national scientific meetings has further addressed its utility. This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use.",
keywords = "Atomoxetine, Attention deficit hyperactivity disorder, Norepinephrine, Psychopharmacology",
author = "Kratochvil, {Christopher J} and Vaughan, {Brigette S.} and Daughton, {Joan M.} and Mayfield-Jorgensen, {Michelle L.} and Burke, {William J.}",
year = "2004",
month = "7",
day = "1",
doi = "10.1586/14737175.4.4.601",
language = "English (US)",
volume = "4",
pages = "601--611",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Atomoxetine in the treatment of attention deficit hyperactivity disorder

AU - Kratochvil, Christopher J

AU - Vaughan, Brigette S.

AU - Daughton, Joan M.

AU - Mayfield-Jorgensen, Michelle L.

AU - Burke, William J.

PY - 2004/7/1

Y1 - 2004/7/1

N2 - Atomoxetine (Strattera™ Eli Lilly & Co.) is a highly selective noradrenaline reuptake inhibitor and the first nonstimulant medication to be approved for the treatment of attention deficit hyperactivity disorder. Currently, nine published clinical trials have documented the safety and efficacy of atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder and data presented throughout the past year at national scientific meetings has further addressed its utility. This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use.

AB - Atomoxetine (Strattera™ Eli Lilly & Co.) is a highly selective noradrenaline reuptake inhibitor and the first nonstimulant medication to be approved for the treatment of attention deficit hyperactivity disorder. Currently, nine published clinical trials have documented the safety and efficacy of atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder and data presented throughout the past year at national scientific meetings has further addressed its utility. This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use.

KW - Atomoxetine

KW - Attention deficit hyperactivity disorder

KW - Norepinephrine

KW - Psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=3042783231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042783231&partnerID=8YFLogxK

U2 - 10.1586/14737175.4.4.601

DO - 10.1586/14737175.4.4.601

M3 - Review article

VL - 4

SP - 601

EP - 611

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 4

ER -